Galway, Ireland – June 2026 – ATU iHub congratulates client company CroíValve on securing $36 million (approximately €33 million) in Series B funding, marking a significant milestone in its growth.
The Irish medtech company is developing a minimally invasive treatment for tricuspid regurgitation, a serious heart condition affecting millions globally.
Professor Grygier, Poznan University of Medical Sciences Team and the CroíValve Team following DUO Adapt cases
The round includes a $20 million (€18.4 million) expansion, alongside $7 million (€6.4 million) in grant funding, bringing total funding linked to the round to $43 million (approximately €39.5 million) including grants.
The investment, backed by BGF, the European Innovation Council and the MedTech Syndicate, will support the expansion of CroíValve’s TANDEM II clinical trial across the US and Europe.
CroíValve’s DUO™ system offers a non-surgical option for patients unsuitable for traditional procedures, aiming to improve outcomes for those living with this complex condition.
ATU iHub is proud to support CroíValve as part of its innovation ecosystem. This funding milestone highlights the strength of Ireland’s medtech sector and the global potential of companies emerging from the iHub network.
About ATU iHub
ATU iHub supports entrepreneurs, start-ups, and scaling companies through incubation, innovation programmes, and access to a dynamic network across Ireland’s west and northwest. The iHub is committed to enabling businesses to grow, scale, and achieve global impact.
About CroíValve
CroíValve is an Irish clinical-stage medical device company focused on developing innovative, minimally invasive solutions to treat tricuspid regurgitation, a serious and often overlooked heart condition. Its proprietary DUO™ system is designed to restore valve function without the need for open-heart surgery, improving outcomes for patients who are unsuitable for conventional treatments. With operations spanning Ireland and the United States, CroíValve is advancing clinical studies to bring its breakthrough technology to patients worldwide.